TCT
TAVR cost-saving vs. surgery in low-risk patients at 2 years
In an economic analysis from the PARTNER 3 trial, transcatheter aortic valve replacement was economically dominant compared with surgery at 2 years in patients with severe aortic stenosis at low surgical risk.
SURTAVI: TAVR remains noninferior to surgery in intermediate-risk patients at 5 years
Transcatheter aortic valve replacement with a self-expanding valve was noninferior to surgical AVR in intermediate-risk patients at 5 years, according to new data from the SURTAVI trial.
PCI guided by quantitative flow ratio confers better 1-year outcomes vs. standard PCI
PCI guided by quantitative flow ratio, a novel approach to estimate fractional flow reserve, was associated with lower rates of MACE at 1 year compared with PCI guided by angiography, according to results of the FAVOR III China trial.
Ultrasound renal denervation may be beneficial in hypertension at 6 months
Ultrasound renal denervation in patients with triple-therapy resistant hypertension remained effective at 6 months, according to new data from RADIANCE-HTN TRIO reported at TCT 2021.
FFR-guided PCI for three-vessel CAD not noninferior to surgery at 1 year: FAME 3
In the FAME 3 trial, PCI guided by fractional flow reserve failed to meet noninferiority for reduction of MACCE at 1 year compared with CABG in patients with three-vessel CAD.
The Take Home: TCT Connect
Due to the COVID-19 pandemic, the Transcatheter Cardiovascular Therapeutics meeting was held virtually. TCT Connect, which ran from Oct. 14 to 18, offered the latest in cutting-edge science for interventional cardiologists.